Leibniz photonics institute specializing in biomedical optical imaging, fibre sensor systems, and photonics innovation support for SMEs.
The Leibniz Institute of Photonic Technology (Leibniz-IPHT) in Jena develops advanced optical and photonic technologies for biomedical imaging, sensing, and materials science. Their core competence lies in translating photonics research into practical instruments — from fibre-optic sensors and micro-endoscopes to Raman spectroscopy platforms for disease diagnosis. They design and fabricate specialty optical fibres, nanocrystal-doped laser materials, and microfluidic photonic devices, bridging the gap between fundamental optics research and clinical or industrial application. They also serve as an access hub for SMEs seeking photonics prototyping and innovation support.
Core across LIFEGATE (holographic micro-endoscopy), MIB and MOON (multi-modal diagnostics), CRIMSON (coherent Raman imaging), IMAGE-IN (infection imaging), PHAST (cancer biophotonics), and FILM-HIV (super-resolution HIV imaging).
FINESSE developed distributed fibre sensing systems, NCLas created nanocrystal-doped fibre lasers, and PHAST uses multifunctional fibre sensors for clinical applications.
ACTPHAST 4.0, ACTPHAST 4R, PhotonHub Europe, and SMARTER-SI all provide access services, prototyping, and technology transfer for SMEs and industry.
QUANTUM E-LEAPS (quantum metrology via phase slips) and SUPERGALAX (single microwave photon detection with superconducting qubits) mark a recent expansion into quantum technologies.
CRIMSON focuses on CARS and SRS imaging, LOGIC LAB on molecular spectroscopy in microfluidics, and PHAST applies Raman spectroscopy to cancer diagnosis.
In the early H2020 period (2015–2018), IPHT focused on smart systems integration, distributed fibre-optic sensing, and general photonics access services for industry. From 2019 onward, the institute shifted decisively toward biomedical photonics — particularly Raman-based molecular imaging, super-resolution microscopy for disease research, and infection/cancer diagnostics — while also branching into quantum metrology and superconducting detector technologies. The trend shows a lab moving from enabling general photonics applications to becoming a specialized biomedical imaging powerhouse with a growing quantum measurement arm.
IPHT is converging on clinical biophotonics (cancer, infection, disease imaging) as its dominant research direction, making them an increasingly strong partner for health-sector photonics projects.
IPHT balances leadership and partnership roles — they coordinated 6 of 19 projects (32%), typically in areas where they bring unique optical instrumentation capabilities (micro-endoscopy, fibre lasers, super-resolution imaging). As participants, they integrate into large multi-country consortia, contributing specialized photonics modules rather than managing entire programmes. With 201 unique partners across 24 countries, they operate as a well-connected hub rather than a closed-circle institute, which signals openness to new collaborations.
IPHT has worked with 201 distinct consortium partners across 24 countries, establishing one of the broader photonics collaboration networks in Europe. Their partnerships span from clinical research hospitals to photonics SMEs and large innovation platforms like PhotonHub Europe.
IPHT occupies a rare niche: they combine deep photonics fabrication capabilities (specialty fibres, optical components, microfluidic devices) with direct biomedical application expertise. Unlike university optics groups that stay theoretical, or medical device companies that buy off-the-shelf components, IPHT designs custom photonic instruments from materials up to clinical prototype. Their dual role as both a research performer and SME innovation access point (via ACTPHAST, PhotonHub) means they can bridge research consortia and industry partners within a single organization.
